Neonates, infants, and children differ from adults in many aspects, not just in age, weight,
and body composition. Growth, maturation and environmental factors affect drug kinetics …

Pharmacometric analyses have become an increasingly important component of New Drug
Application (NDA) and Biological License Application (BLA) submissions to the US FDA to …

Irrespective of whether a drug is in development or already available on the market, the
current paradigm for paediatric dose selection does not guarantee safe and effective dosing …

Background Critically ill children frequently display observed alterations of pharmacokinetic
(PK) parameters, leading to a reduction in β-lactam concentrations. This study aimed to …

The objective of this work was to derive a dosing regimen for dabigatran in patients with
severe renal impairment by modeling and simulation. Data from a dedicated renal …

Objectives: To characterize the population pharmacokinetics of piperacillin and tazobactam
in critically ill infants and children, in order to develop an evidence-based dosing regimen …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of extended-infusion piperacillin-tazobactam in children hospitalized in …

The objective was to characterize the pharmacokinetics (PK) and pharmacodynamics (PD)
of argatroban in pediatric patients and derive dosing recommendations. An open‐label …

Objectives To develop population pharmacokinetic (PK) models for piperacillin/tazobactam
in neonates and infants of less than 2 months of age in order to determine the appropriate …

Objectives: Little is known on the impact of continuous renal replacement therapy on
antimicrobial dose requirements in children. In this study, we evaluated the …